Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?

被引:67
作者
O'Keefe, JH
Wetzel, M
Moe, RR
Brosnahan, K
Lavie, CJ
机构
[1] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA
[2] Ochsner Heart & Vasc Inst, New Orleans, LA USA
关键词
D O I
10.1016/S0735-1097(00)01044-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin-converting enzyme (ACE) inhibitors appear to possess unique cardioprotective benefits, even when used in patients without high blood pressure or left ventricular dysfunction (the traditional indications for ACE inhibitor therapy). The ACE inhibitors improve endothelial function and regress both left ventricular hypertrophy and arterial mass better than other antihypertensive agents that lower blood pressure equally as well. These agents promote collateral vessel development and improve prognosis in patients who have had a coronary revascularization procedure (i.e., percutaneous transluminal coronary angioplasty and coronary artery bypass graft surgery). Insulin resistance, present not only in type 2 diabetes but also commonly in patients with hypertension or coronary artery disease, or both, sensitizes the vasculature to the trophic effects of angiotensin II and aldosterone. This may partly explain the improvement in prognosis noted when patients who have atherosclerosis or diabetes are treated with an ACE inhibitor. Therapy with ACE inhibitors has also been shown, in two large, randomized trials, to reduce the incidence of new-onset type 2 diabetes through largely unknown mechanisms. The ACE inhibitors are safe, well tolerated and affordable medications. The data suggest that most people with atherosclerosis should be considered candidates for ACE inhibitor therapy, unless they are intolerant to the medication, or have systolic blood pressures consistently <100 mm Hg. Patients who show evidence of insulin resistance (with or without overt type 2 diabetes) should also be considered as candidates for prophylactic ACE inhibitor therapy. Although angiotensin receptor blockers should not be considered equivalent to ACE inhibitors for this indication, they may be a reasonable alternative for patients intolerant of ACE inhibitors. (J Am Coil Cardiol 2001;37: 1-8) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 52 条
[1]   Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) [J].
Anderson, TJ ;
Elstein, E ;
Haber, H ;
Charbonneau, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (01) :60-66
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[3]  
BALL SG, 1993, LANCET, V342, P821
[4]  
BOUR LMB, 1995, BRIT HEART J, V73, P227
[5]  
Chalmers J, 1999, CLIN EXP HYPERTENS, V21, P1009
[6]   Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction - A meta-analysis of randomized clinical trials [J].
Domanski, MJ ;
Exner, DV ;
Borkowf, CB ;
Geller, NL ;
Rosenberg, Y ;
Pfeffer, MA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :598-604
[7]   The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension [J].
Estacio, RO ;
Jeffers, BW ;
Hiatt, WR ;
Biggerstaff, SL ;
Gifford, N ;
Schrier, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (10) :645-652
[8]   Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo [J].
Fabre, JE ;
Rivard, A ;
Magner, M ;
Silver, M ;
Isner, JM .
CIRCULATION, 1999, 99 (23) :3043-3049
[9]   Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function [J].
Frances, CD ;
Noguchi, H ;
Massie, BM ;
Browner, WS ;
McClellan, M .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (17) :2645-2650
[10]   ACE inhibition in cardiovascular disease [J].
Francis, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (03) :201-202